Moreover, positive correlations between its expression and EGFR-TKI resistance, CD8+ T cell infiltration and tumor proportion score (TPS) in LUAD were validated in patients’ samples, emphasizing its potential in guiding personalized therapy. This evidence concerns the gene CD8A and neoplasm.